SLC5A2 and kidney disorder: Our findings on SGLT-2 inhibitors are consistent with recent meta-analyses of CVOTs on this drug class [17, 39], in which SGLT-2 inhibitors were found to reduce MACE, cardiovascular mortality, hospitalisation for HF, and progression of renal disease in patients with atherosclerotic cardiovascular disease.